Industry Reports

You have selected:


Publisher:

Sociable Pharma

Sort By:
Report Status:
9 Report Results
Page 1 of 1
Go To Page:
    
  Go

Asthma: KOL insights on treatment practices and unmet needs

$2,795.00
By:
, Published: Oct-2011

Sociable Pharma conducted in-depth primary research in the US and across Europe with six key opinion leaders to understand how these changes will impact therapy use in the future. We also gauged opinion during the European Respiratory Society's 2011 Annual Congress on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by asthma specialists.

Chronic Obstructive Pulmonary Disease (COPD): KOL insights on treatment practices and unmet needs

$2,795.00
By:
, Published: Oct-2011

Sociable Pharma conducted in-depth primary research in the US and across Europe with seven key opinion leaders to understand how these changes will impact therapy use in the future. We also gauged opinion during the European Respiratory Society's 2011 Annual Congress on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by COPD specialists.

Rheumatoid Arthritis: KOL insights on treatment practices and unmet needs

$2,795.00
By:
, Published: Oct-2011

Sociable Pharma conducted in-depth primary research in the US and across Europe with six key opinion leaders in rheumatoid arthritis (RA) to understand how changes will impact therapy use in the future. A key theme in our research is the management and implementation of ‘step-up’ treatment strategies to optimize the timing of effective forms of therapy. Our view is that this is the major macro-trend that will alter treatment strategies, genera.....

Juvenile Idiopathic Arthritis (JIA): KOL insights on treatment practices and unmet needs

$2,795.00
By:
, Published: Oct-2011

Sociable Pharma conducted in-depth primary research in the US and across Europe with seven key opinion leaders in juvenile idiopathic arthritis (JIA) to understand how therapy use will change in the future. A key theme in our research is the management and implementation of ‘step-up’ treatment strategies to optimize the timing of effective forms of therapy. Our view is that this is the major macro-trend that will alter treatment strategy, gene.....

Ulcerative Colitis: KOL insights on treatment practices and unmet needs

$3,400.00
By:
, Published: Apr-2011

The use of biologics is still in its formative stages in the treatment of ulcerative colitis but adoption has already been significant and is set to expand considerably in the short- and medium-term. Sociable Pharma conducted in-depth primary research in the US and Europe with key opinion leaders to understand how these changes will impact therapy use in the future. We also gauged opinion during the European Crohn's & Colitis Organisation's (E.....

Crohn’s disease: KOL insights on treatment practices and unmet needs

$3,400.00
By:
, Published: Apr-2011

Changes in therapeutic strategies for Crohn's disease are set to have a profound impact on its treatment landscape, exacerbating current and generating new treatment challenges for doctors, while presenting new and potentially lucrative opportunities for current and future market players. Sociable Pharma conducted in-depth primary research in the US and across Europe with six key opinion leaders to understand how these changes will impact ther.....

Crohn’s disease: future treatment scenarios and opportunities

$3,400.00
By:
, Published: Apr-2011

Changes in therapeutic strategies for Crohn's disease are set to have a profound impact on its treatment landscape, exacerbating current and generating new treatment challenges for doctors, while presenting new and potentially lucrative opportunities for current and future market players. Sociable Pharma conducted in-depth primary research in the US and across Europe with six key opinion leaders to understand how these changes will impact ther.....

5-Aminosalicylate Therapies in IBD: opinion leader insight into current & future treatment practices

$1,600.00
By:
, Published: Apr-2011

5-aminosalicylate therapies form a fundamental part of the treatment of both Crohn’s disease and ulcerative colitis. However, while new therapies and data continue to cement the place of 5-ASAs as first-line options for most patients in ulcerative colitis, meta-analysis has undermined doctor confidence in Crohn’s disease. Sociable Pharma conducted in-depth primary research in the US and across Europe with key opinion leaders to understand how .....

Anti-TNF Therapies in IBD: opinion leader insight into current & future treatment practices

$1,600.00
By:
, Published: Apr-2011

Since the introduction of infliximab for the treatment of Crohn’s disease in 1999, anti-TNF therapies have begun to reshape the treatment landscape for inflammatory bowel disease. There are now well-established treatment strategies for biologics in both Crohn’s disease and ulcerative colitis but it will be the movement of anti-TNF therapies to earlier treatment settings in both diseases that will be the dominant macro-trend in the future. Soci.....